Navigation Links
Logical Therapeutics Secures $16.9M Series C Financing Round
Date:5/26/2010

Lead Candidate, LT-NS001, Shows Evidence of Improved GI Safety for Arthritis Patients

WALTHAM, Mass., May 26 /PRNewswire/ -- Logical Therapeutics, Inc., a private, clinical stage biopharmaceutical company, announced today it had closed on a $16.9 million Series C equity financing.  The round was led by existing investor SV Life Sciences, and included Burrill & Company, Novo A/S and Novitas Capital.

Logical Therapeutics is developing a family of new chemical entities using its patented Bio-activated Technology.TM The proprietary platform, which modifies the chemical structure of NSAIDs (non-steroidal anti-inflammatory drugs), is being developed to significantly reduce the gastrointestinal (GI) side effects often associated with NSAIDs.  The Company's lead compound, LT-NS001 (naproxen etemesil), is currently being studied in a Phase 2b/3 study comparing the cumulative rate of gastric ulcers vs. Naprosyn® in osteoarthritis patients after 12 weeks of treatment.  Completion of the study is expected in late 2010.

The Series C financing round is expected to provide sufficient capital to advance the Company's development program through further clinical and non-clinical activities necessary for registration. The Company intends to seek a business partner prior to commercialization.  

About Logical Therapeutics, Inc.

Based in Waltham, MA, Logical Therapeutics, Inc. is a venture-backed, privately held biopharmaceutical company focused on the development of bio-activated prodrugs to treat inflammatory conditions such as osteoarthritis and rheumatoid arthritis.  The Company's Bio-activated TechnologyTM has created a portfolio of molecules including LT-NS001, a naproxen prodrug and several additional bio-activated NSAID prodrug candidates, which are covered by issued and pending U.S. and international patents.  Each program addresses unmet medical needs in multi-billion dollar markets.  For more information about Logical Therapeutics, visit the Company's website at www.logicaltx.com.

LT-NS001 is an investigational drug product candidate undergoing clinical evaluation and has not been approved by the U.S. Food and Drug Administration.

Bio-activated TechnologyTM is a trademark of Logical Therapeutics, Inc.


'/>"/>
SOURCE Logical Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Alzheimers Drug Discovery Foundation Funds Amicus Therapeutics To Advance Pharmacological Chaperone Technology
2. Logical Therapeutics Initiates Enrollment in New Gastrointestinal Safety Study in Osteoarthritis Patients
3. Neurobiological Technologies Announces Filing of Certificate of Dissolution and Closing of Stock Transfer Books
4. Tuesday, Dec. 1: News From the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) in Chicago
5. Bayer HealthCare Pharmaceuticals Initiates Phase III Trial with Florbetaben PET Tracer for Imaging of Cerebral beta-Amyloid Plaques, a Pathological Hallmark of Alzheimers Disease
6. Monday, Nov. 30: News From the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) in Chicago
7. Varian Medical Systems to Highlight the Latest Digital Detectors, X-ray Tubes and Cancer Treatment Technology at the Radiological Society of North America (RSNA) Annual Meeting in Chicago
8. China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits
9. Neurobiological Technologies Announces Extraordinary Dividend of $0.18 per Share
10. Reportlinker Adds Audiological Devices - Global Market Trends
11. EntreMeds ENMD-2076 Active in Solid and Hematological Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... , May 26, 2017  Endo International plc (NASDAQ: ... President and CEO, will represent the Company in a fireside ... Conference on Tuesday, June 13, 2017 at 10:40 a.m. PT ... Terranea Resort in Rancho Palos Verdes, CA. ... the event will be available on the Company,s website at ...
(Date:5/22/2017)... 22, 2017  Lilac Corp, the company that ... launch of a new website . The ... a clinical study that showed surprising clearance of ... in individuals suffering from HPV warts, precancerous, or ... are no other treatments that clear the virus. ...
(Date:5/15/2017)... , May 15, 2017  Amy Baxter MD, ... industry leader in noninvasive pain relief, was awarded a ... magazine. Baxter was recognized at the MM&M Top ... New York City on May 10, 2017. ... the biopharma industry go "beyond the pill."  ...
Breaking Medicine Technology:
(Date:5/28/2017)... City, FL (PRWEB) , ... May 28, 2017 , ... ... be treated with Nerve-Express, the latest Heart Rate Variability (HRV) diagnostic test. , Nerve-Express, ... heart rate and R-R interval, indicating the state of a patient’s autonomic nervous system ...
(Date:5/27/2017)... ... , ... A May 8 article on CBCNews reports that nearly ... that are not responsive to antibiotics nevertheless obtain prescriptions for them. The article goes ... the problem both in Canada and the United States. Dr. Michael Farzam of House ...
(Date:5/26/2017)... ... 26, 2017 , ... Mediaplanet is proud to announce the launch of its ... will educate readers on how to take care of all aspects of their skin. ... on melanoma. Dancing with the Stars professional, Witney Carson, shares her journey with the ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... ... integration of the CareFusion NOX-T3 portable sleep monitor with its Somnoware Sleep Device ... consistent, browser-based interface for diagnostic device operations. With this platform, initializing devices and ...
(Date:5/26/2017)... ... May 26, 2017 , ... After raising nearly $30,000 on ... continue to be available at a discounted crowdfunding price on Indiegogo . , ... are, I also wanted to bring a fidget toy to the market that was ...
Breaking Medicine News(10 mins):